Shares of Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $9.39, but opened at $9.11. Teladoc Health shares last traded at $9.35, with a volume of 410,283 shares traded.
Analyst Ratings Changes
A number of research firms have commented on TDOC. Oppenheimer cut their price target on shares of Teladoc Health from $14.00 to $12.00 and set an "outperform" rating for the company in a research note on Friday, January 24th. The Goldman Sachs Group cut their price target on shares of Teladoc Health from $16.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Piper Sandler decreased their price objective on Teladoc Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Needham & Company LLC restated a "hold" rating on shares of Teladoc Health in a report on Thursday, February 27th. Finally, Royal Bank of Canada lifted their price target on Teladoc Health from $11.00 to $12.00 and gave the stock an "outperform" rating in a research note on Friday, January 24th. Eleven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Teladoc Health currently has a consensus rating of "Hold" and a consensus price target of $11.26.
Check Out Our Latest Stock Report on Teladoc Health
Teladoc Health Stock Performance
The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The firm has a market cap of $1.52 billion, a P/E ratio of -1.52 and a beta of 1.27. The business has a fifty day simple moving average of $10.62 and a 200-day simple moving average of $9.66.
Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.07). Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The business had revenue of $640.49 million during the quarter, compared to the consensus estimate of $639.44 million. On average, sell-side analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Brucke Financial Inc. bought a new position in shares of Teladoc Health during the fourth quarter valued at $92,000. Vise Technologies Inc. increased its stake in Teladoc Health by 4.9% during the 4th quarter. Vise Technologies Inc. now owns 30,179 shares of the health services provider's stock valued at $274,000 after purchasing an additional 1,405 shares in the last quarter. PharVision Advisers LLC purchased a new position in Teladoc Health in the fourth quarter worth about $301,000. Twinbeech Capital LP raised its holdings in Teladoc Health by 63.8% in the fourth quarter. Twinbeech Capital LP now owns 382,735 shares of the health services provider's stock worth $3,479,000 after buying an additional 149,118 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Teladoc Health by 213.0% during the fourth quarter. Two Sigma Advisers LP now owns 2,258,711 shares of the health services provider's stock valued at $20,532,000 after buying an additional 1,537,094 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company's stock.
Teladoc Health Company Profile
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Further Reading
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
